OPKO Health
OPKO Health, Inc. is a multinational healthcare company that operates in the diagnostics and pharmaceuticals sectors. Its Diagnostics segment includes BioReference Laboratories, which provides a range of laboratory testing services, including core genetic testing and the 4Kscore prostate cancer test. The Pharmaceuticals segment offers several treatments, including Rayaldee for secondary hyperparathyroidism, and is developing drugs such as OPK88004, a selective androgen receptor modulator, and OPK88003 for type 2 diabetes and obesity. Additionally, OPKO is advancing hGH-CTP, a once-weekly human growth hormone injection, and has various products targeting chemotherapy-induced nausea, hemophilia, and other medical conditions. The company also engages in the development and commercialization of specialty active pharmaceutical ingredients and a range of pharmaceutical, nutraceutical, and veterinary products. With operations spanning countries such as Ireland, Chile, Spain, and Mexico, OPKO Health focuses on leveraging its proprietary technologies and expertise to grow in key medical markets. Headquartered in Miami, Florida, OPKO Health was incorporated in 1991.
Top Stages
18 past transactions
ModeX Therapeutics
Acquisition in 2022
ModeX Therapeutics is a manufacturer and developer of immune therapy drugs.
HealthSnap
Venture Round in 2021
HealthSnap, Inc. is a healthcare technology company that specializes in developing solutions for processing patient lifestyle data. Incorporated in 2015 and based in Miami, Florida, with an additional location in San Mateo, California, HealthSnap offers a comprehensive Virtual Care Management Platform. This platform enables healthcare organizations to enhance patient outcomes and streamline care management through tools such as Remote Patient Monitoring (RPM) and Chronic Care Management (CCM). By standardizing the collection and analysis of lifestyle health data, HealthSnap assists providers in effectively integrating this information to prevent chronic diseases. The company's technology also utilizes artificial intelligence for care coordination and automates billing processes, thereby aiding clinicians in managing and preventing chronic conditions linked to lifestyle factors.
VBI Vaccines
Post in 2017
VBI Vaccines Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, with research facilities in Ottawa, Canada. It develops and sells vaccines for infectious diseases and immuno-oncology, with a focus on expanding protection in large, underserved markets. The company's enveloped virus-like particle (eVLP) platform enables the creation of vaccines that closely mimic target viruses, eliciting potent immune responses. VBI's commercial product, Sci-B-Vac, is a hepatitis B vaccine approved in Israel and 14 other countries, offering rapid onset of protection and high antibody levels. The company is also developing VBI-2601 for a functional cure of chronic hepatitis B, VBI-1901 for glioblastoma, and VBI-1501 for cytomegalovirus, among other candidates. VBI collaborates with pharmaceutical companies and research institutions, and its products are primarily distributed through direct sales to physicians and pharmacists.
Eloxx
Series C in 2017
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of novel drugs targeting rare and ultra-rare genetic diseases caused by nonsense mutations. Founded in 2013, the company is focused on discovering and commercializing ribonucleic acid modulating drug candidates. Its lead investigational product, ELX-02, is currently undergoing Phase 2 clinical trials aimed at treating cystic fibrosis and nephropathic cystinosis in patients with specific nonsense mutations. Eloxx utilizes its advanced technology platform to create oral small molecules that can induce ribosomal readthrough, thereby enabling the production of full-length functional proteins. The company is building a robust pipeline of therapeutic candidates designed to address various genetic disorders, including Duchenne Muscular Dystrophy and Tay-Sachs syndrome, by overcoming the limitations posed by premature stop codons.
Phio Pharmaceuticals
Post in 2016
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company based in Marlborough, Massachusetts, focusing on the development of immuno-oncology therapeutics. The company utilizes its proprietary INTASYL technology platform, which enables the creation of self-delivering RNA interference (RNAi) therapies aimed at enhancing the immune system's ability to combat cancer. Phio's lead therapeutic candidates include PH-762, targeting the PD-1 checkpoint protein, PH-804, which addresses the TIGIT receptor on immune cells, and PH-790, aimed at the PD-L1 protein that inhibits immune response. These compounds are designed to silence genes that tumors exploit to evade immune detection, thus improving the effectiveness of adoptive cell transfer therapies. Phio Pharmaceuticals has established collaborations with notable institutions such as Gustave Roussy, Medigene AG, and Helmholtz Zentrum München. The company was originally incorporated in 2011 under the name RXi Pharmaceuticals Corporation, which was changed to Phio Pharmaceuticals in November 2018.
Transition Therapeutics
Acquisition in 2016
Transition Therapeutics Inc. is a biopharmaceutical company based in Toronto, Canada, focused on researching and developing therapeutic agents for various diseases. Its lead product, ELND005, targets agitation and aggression associated with Alzheimer's disease and has completed Phase II/III clinical trials. Additionally, Transition is developing TT401, a treatment for type 2 diabetes and obesity, which is currently in Phase II clinical studies. The company is also advancing TT701, a selective androgen receptor modulator aimed at addressing androgen deficiencies. Transition Therapeutics has established a licensing and collaboration agreement with Eli Lilly to further develop TT401 and related compounds that provide glycemic control and other benefits. Founded in 1987 and originally known as Transition Therapeutics and Diagnostics Inc., the company rebranded in December 2000 and operates as a subsidiary of Opko Health, Inc.
VBI Vaccines
Post in 2016
VBI Vaccines Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, with research facilities in Ottawa, Canada. It develops and sells vaccines for infectious diseases and immuno-oncology, with a focus on expanding protection in large, underserved markets. The company's enveloped virus-like particle (eVLP) platform enables the creation of vaccines that closely mimic target viruses, eliciting potent immune responses. VBI's commercial product, Sci-B-Vac, is a hepatitis B vaccine approved in Israel and 14 other countries, offering rapid onset of protection and high antibody levels. The company is also developing VBI-2601 for a functional cure of chronic hepatitis B, VBI-1901 for glioblastoma, and VBI-1501 for cytomegalovirus, among other candidates. VBI collaborates with pharmaceutical companies and research institutions, and its products are primarily distributed through direct sales to physicians and pharmacists.
Arno Therapeutics
Post in 2016
Arno Therapeutics, Inc. is a biopharmaceutical company based in Flemington, New Jersey, dedicated to developing innovative treatments for cancer and other life-threatening diseases. The company's product pipeline includes Onapristone, a type 1 anti-progestin hormone blocker currently undergoing Phase I/II clinical studies for various solid tumors, including breast and endometrial cancers in post-menopausal women and advanced castration-resistant prostate cancer in men. Additionally, Arno is advancing AR-12, an orally available cancer treatment that has completed Phase I studies for solid tumors and hematological malignancies, as well as AR-42, another oral therapy currently in Phase I investigator-initiated studies targeting hematological malignancies and solid tumors. The company has established collaboration agreements with several institutions, enhancing its research and development efforts.
Bio-Reference Laboratories
Acquisition in 2015
BioReference is the third largest full service clinical diagnostic laboratory in the U.S. providing testing and related services to physician offices, clinics, hospitals, long term care facilities, employers, governmental units and correctional institutions. We offer a comprehensive test list focusing on molecular diagnostics, anatomical pathology, genetics, and women’s health. Moreover, through its GeneDx subsidiary, BioReference has an international presence in more than 50 countries around the world.
EirGen Pharma
Acquisition in 2015
EirGen Pharma Ltd. is a pharmaceutical company based in Waterford, Ireland, specializing in the development, registration, and commercial manufacture of high potency solid dose products for the global market. Founded in 2004, the company focuses on oncology, cytotoxic, steroidal, and immunosuppressant molecules, producing these in a purpose-built high containment facility. EirGen Pharma's offerings include clinical trial management, drug formulation development, and contract manufacturing services, producing various dosage forms such as film-coated tablets, soft-gel capsules, and specialized veterinary products. The company is licensed to manufacture investigational medicinal products and has facilities designed to handle moisture-sensitive molecules in controlled environments. EirGen Pharma operates across multiple regions, including the United States, Europe, Japan, Canada, Australia, the Middle East, and Africa.
Inspiro Medical
Acquisition in 2014
Inspiro Medical Ltd. is a medical device company focused on creating an innovative inhalation platform that facilitates the delivery of both small molecules, including corticosteroids and beta agonists, and larger macromolecules, such as antibodies and vaccines. The company is actively conducting clinical trials involving its proprietary dry powder inhaler, Inspiromatic, specifically targeting children with asthma. Through its advanced technology, Inspiro Medical aims to enhance treatment options for respiratory diseases.
PROLOR Biotech
Acquisition in 2013
PROLOR Biotech is developing proprietary versions of already-approved therapeutic proteins. The Company’s Carboxyl Terminal Peptide technology can be attached to an array of existing therapeutic proteins, stabilizing the therapy in the bloodstream and extending its lifespan without additional toxicity or loss of desired biological activity. PROLOR products under development include Human Growth Hormone (“hGH”) for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone (a $3 billion market opportunity). PROLOR’s hGH could potentially be injected once a week or twice per month instead of daily. PROLOR’s hGH is scheduled for Phase III trials in 2013.
Cytochroma
Acquisition in 2013
Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing prescription products aimed at addressing vitamin D insufficiency and secondary hyperparathyroidism (SHPT) linked to chronic kidney disease (CKD). The company has a portfolio of innovative therapies specifically designed to safely and effectively treat patients with vitamin D deficiency and SHPT across various stages of CKD. Additionally, Cytochroma is working on novel treatments targeting elevated blood phosphorus levels, or hyperphosphatemia, to enhance the management of SHPT in CKD patients.
FineTech Pharmaceutical
Acquisition in 2011
FineTech Laboratories specializes in the development and manufacturing of low volume, high value specialty active pharmaceutical ingredients (APIs). The company focuses on creating APIs through non-infringing processes and polymorphs, which allows it to navigate patent complexities effectively. FineTech's product portfolio includes notable compounds such as cabergoline, latanoprost, travoprost, nabilone, melatonin, and methylbenzethonium chloride. By offering a diverse range of APIs, FineTech Laboratories supports the healthcare sector in meeting its diverse needs and advancing pharmaceutical development.
Claros Diagnostics
Acquisition in 2011
Claros Diagnostics Inc., established in 2015, specializes in developing portable immunoassay systems designed for point-of-care blood testing. Their innovative product comprises a handheld analyzer and disposable cassettes capable of detecting multiple biomarkers simultaneously. This technology enables healthcare professionals and patients to conduct tests for infectious diseases, cancer, and immune disorders outside traditional laboratory settings.
Fabrus
Venture Round in 2010
Fabrus LLC, established in 2007 as the inaugural company in The Pfizer Incubator, specializes in therapeutic antibody discovery and development. The company has developed a distinctive antibody discovery platform that enables high-throughput identification of biologic leads. By utilizing cell-based screening methods, Fabrus allows for direct identification of antibody leads on intact cells. This innovative approach includes the use of ultralong CDR3 antibodies and the chimerasome nanocage, which empower researchers to generate antibodies targeting challenging yet therapeutically significant cell surface receptors. Fabrus has built a skilled scientific team dedicated to advancing its platform and has successfully identified multiple preclinical lead candidates aimed at critical cancer targets.
Vidus Ocular
Acquisition in 2008
Vidus Ocular, Inc. develops an implantable physiologic device that is designed to address the shortcomings of glaucoma treatments. It offers Aquashunt, which is a shunt to treat glaucoma, the cause of blindness in the United States. The company is based in the United States. As of May 7, 2008, Vidus Ocular, Inc. operates as a subsidiary of Opko Health, Inc.
Acuity Pharmaceuticals
Acquisition in 2007
Acuity Pharmaceuticals is a pharmaceutical company based in Philadelphia, Pennsylvania, that specializes in developing treatments for ophthalmic diseases, particularly age-related macular degeneration and diabetic retinopathy. Founded in 2007, the company focuses on innovative therapies, including its clinical compound Cand5, a small interfering RNA therapeutic designed to treat vision loss by targeting vascular endothelial growth factor. In June 2011, Acuity Pharmaceuticals was acquired by OPKO Health, further enhancing its capabilities in the field of eye care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.